WallStSmart

Taseko Mines Ltd (TGB)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Taseko Mines Ltd generates 1295% more annual revenue ($770.85M vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 2.0%. VMET trades at a lower P/E of 37.5x. VMET earns a higher WallStSmart Score of 58/100 (C).

TGB

Buy

55

out of 100

Grade: C-

Growth: 6.7Profit: 5.0Value: 6.0Quality: 3.5
Piotroski: 3/9Altman Z: 0.59

VMET

Buy

58

out of 100

Grade: C

Growth: 10.0Profit: 8.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

TGBUndervalued (+2.3%)

Margin of Safety

+2.3%

Fair Value

$7.31

Current Price

$6.37

$0.94 discount

UndervaluedFair: $7.31Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TGB3 strengths · Avg: 9.3/10
PEG RatioValuation
0.3310/10

Growing faster than its price suggests

Revenue GrowthGrowth
70.4%10/10

Revenue surging 70.4% year-over-year

Operating MarginProfitability
23.4%8/10

Strong operational efficiency at 23.4%

VMET5 strengths · Avg: 9.8/10
Profit MarginProfitability
58.4%10/10

Keeps 58 of every $100 in revenue as profit

Operating MarginProfitability
90.6%10/10

Strong operational efficiency at 90.6%

Revenue GrowthGrowth
594.0%10/10

Revenue surging 594.0% year-over-year

EPS GrowthGrowth
573.0%10/10

Earnings expanding 573.0% YoY

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Areas to Watch

TGB4 concerns · Avg: 3.0/10
Return on EquityProfitability
1.9%3/10

ROE of 1.9% — below average capital efficiency

Profit MarginProfitability
2.0%3/10

2.0% margin — thin

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Market CapQuality
$1.26B3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : TGB

The strongest argument for TGB centers on PEG Ratio, Revenue Growth, Operating Margin. Revenue growth of 70.4% demonstrates continued momentum. PEG of 0.33 suggests the stock is reasonably priced for its growth.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.

Bear Case : TGB

The primary concerns for TGB are Return on Equity, Profit Margin, Debt/Equity. A P/E of 187.5x leaves little room for execution misses. Thin 2.0% margins leave little buffer for downturns.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

TGB profiles as a hypergrowth stock while VMET is a growth play — different risk/reward profiles.

VMET is growing revenue faster at 594.0% — sustainability is the question.

TGB generates stronger free cash flow (43M), providing more financial flexibility.

Monitor COPPER industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VMET scores higher overall (58/100 vs 55/100), backed by strong 58.4% margins and 594.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Taseko Mines Ltd

BASIC MATERIALS · COPPER · USA

Taseko Mines Limited, a mining company, acquires, develops and operates mineral properties. The company is headquartered in Vancouver, Canada.

Visit Website →

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing cutting-edge therapeutics for serious diseases, leveraging its proprietary metalloenzyme-based technology platform. The company is committed to addressing significant unmet medical needs in fungal infections and oncology, positioning itself as a leader in therapeutic innovation. With a diverse pipeline bolstered by strategic collaborations and a strong intellectual property portfolio, Viamet is well-prepared to advance its clinical initiatives and enhance shareholder value, aiming to redefine treatment approaches in its specialized therapeutic areas.

Want to dig deeper into these stocks?